Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Autor: Chen EX; Princess Margaret Cancer Center, Toronto, Ontario, Canada., Loree JM; British Columbia Cancer Agency, Vancouver, Canada., Titmuss E; British Columbia Cancer Agency, Vancouver, Canada., Jonker DJ; The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada., Kennecke HF; Portland Providence Cancer Center, Earle Chiles Research Institute, Portland, Oregon., Berry S; Department of Oncology, Queen's University, Kingston, Ontario, Canada., Couture F; L'Hôtel-Dieu de Québec, Laval, Quebec, Canada., Ahmad CE; Eastern Health, St John's, Newfoundland and Labrador, Canada., Goffin JR; Juravinski Cancer Center, Hamilton, Ontario, Canada., Kavan P; Segal Cancer Center, Montreal, Quebec, Canada., Harb M; Moncton Hospital, Moncton, Brunswick, Canada., Colwell B; Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada., Samimi S; Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada., Samson B; Charles LeMoyne Hospital Cancer Centre, Sherbrooke, Quebec, Canada., Abbas T; Saskatoon Cancer Center, Saskatoon, Saskatoon, Canada., Aucoin N; Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada., Aubin F; Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada., Koski S; Cross Cancer Center, Edmonton, Alberta, Canada., Wei AC; Memorial Sloan Kettering Cancer Center, New York, New York., Tu D; Canadian Cancer Trials Group, Kingston, Ontario, Canada., O'Callaghan CJ; Canadian Cancer Trials Group, Kingston, Ontario, Canada.

Publikováno v: JAMA network open [JAMA Netw Open] 2023 Dec 01; Vol. 6 (12), pp. e2346094. Date of Electronic Publication: 2023 Dec 01.

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.

Autor: Renouf DJ; Pancreas Centre BC, Vancouver, BC, Canada. drenouf@bccancer.bc.ca.; Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada. drenouf@bccancer.bc.ca., Loree JM; Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Knox JJ; Princess Margaret Cancer Centre, UHN, University of Toronto, Toronto, ON, Canada., Topham JT; Pancreas Centre BC, Vancouver, BC, Canada., Kavan P; Department of Medicine and Oncology, Sir Mortimer B. Davis Jewish General Hospital, Segal Cancer Centre, McGill University, Montreal, QC, Canada., Jonker D; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Welch S; London Regional Cancer Program, London, ON, Canada., Couture F; CHU de Quebec Research Centre and Faculty of Medicine, Laval University, Quebec City, QC, Canada., Lemay F; Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada., Tehfe M; Hematology and Medical Oncology Division, Centre Hospitalier Universitaire de Montreal, University of Montreal, Montreal, QC, Canada., Harb M; The Moncton City Hospital, Moncton, NB, Canada., Aucoin N; Hopital Cite-de-la-Sante, Laval, QC, Canada., Ko YJ; Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada., Tang PA; University of Calgary, Calgary, AB, Canada., Ramjeesingh R; Nova Scotia Cancer Centre and Dalhousie University, Halifax, NS, Canada., Meyers BM; Juravinski Cancer Centre, Hamilton, ON, Canada., Kim CA; CancerCare Manitoba, Winnipeg, MB, Canada., Du P; Predicine, Inc., Hayward, CA, USA., Jia S; Predicine, Inc., Hayward, CA, USA., Schaeffer DF; Pancreas Centre BC, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.; Division of Anatomic Pathology, Vancouver General Hospital, Vancouver, BC, Canada., Gill S; Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Tu D; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., O'Callaghan CJ; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.

Publikováno v: Nature communications [Nat Commun] 2022 Aug 26; Vol. 13 (1), pp. 5020. Date of Electronic Publication: 2022 Aug 26.

Radiomics-Based Machine Learning with Natural Gradient Boosting for Continuous Survival Prediction in Glioblastoma.

Autor: Karabacak, Mert¹ (AUTHOR) mert.karabacak@mountsinai.org, Patil, Shiv² (AUTHOR) shiv.patil@students.jefferson.edu, Gersey, Zachary Charles³ (AUTHOR) zgersey@med.miami.edu, Komotar, Ricardo Jorge³ (AUTHOR) rkomotar@med.miami.edu, Margetis, Konstantinos¹ (AUTHOR) konstantinos.margetis@mountsinai.org

Publikováno v: Cancers. Nov2024, Vol. 16 Issue 21, p3614. 11p.

Conditional probabilistic diffusion model driven synthetic radiogenomic applications in breast cancer.

Autor: Chen, Lianghong¹ (AUTHOR), Huang, Zi Huai² (AUTHOR), Sun, Yan^1,2 (AUTHOR), Domaratzki, Mike¹ (AUTHOR), Liu, Qian³ (AUTHOR) qi.liu@uwinnipeg.ca, Hu, Pingzhao^1,2,4,5,6 (AUTHOR) phu49@uwo.ca

Publikováno v: PLoS Computational Biology. 10/7/2024, Vol. 20 Issue 10, p1-24. 24p.

MRI-Based Machine Learning for Prediction of Clinical Outcomes in Primary Central Nervous System Lymphoma.

Autor: Ko, Ching-Chung^1,2,3 (AUTHOR) kocc0729@gmail.com, Liu, Yan-Lin⁴ (AUTHOR) yalin0917@gmail.com, Hung, Kuo-Chuan^5,6 (AUTHOR) ed102605@gmail.com, Yang, Cheng-Chun¹ (AUTHOR), Lim, Sher-Wei^7,8 (AUTHOR) slsw0219@gmail.com, Yeh, Lee-Ren^9,10,11 (AUTHOR) ed103639@edah.org.tw, Chen, Jeon-Hor^4,9 (AUTHOR) jeonhc01@gmail.com, Su, Min-Ying⁴ (AUTHOR) msu@uci.edu

Publikováno v: Life (2075-1729). Oct2024, Vol. 14 Issue 10, p1290. 14p.